NEJM: Cemiplimab for Recurrent Cervical Cancer

The prognosis for patients with recurrent cervical cancer is often poor
.

Cemiplimab, a fully human PD-1 antibody, has been approved by the FDA for first-line treatment of tumors with high PD-L1 expression (TPS≥50%), metastatic or locally advanced tumors that are not suitable for surgical resection or radical radiotherapy Chemotherapy, non-small cell lung cancer and skin cancer whose tumors do not have EGFR, ALK, or ROS1 aberrations

FDA Lung Cancer

This study is a phase 3 clinical trial recruiting patients with cervical cancer (regardless of their PD-L1 status) who have progressed after first-line platinum-containing chemotherapy regimens
.

Patients were randomized 1:1 to receive either cemiplimab (350 mg/3 weeks) or single-agent chemotherapy of the investigator's choice

Overall survival of patients in the two treatment groups

Overall survival of patients in the two treatment groups

A total of 608 patients (304 in each group) were recruited
.

In the overall trial population, median overall survival was significantly longer in the cemiplimab group than in the chemotherapy group (12.

The median overall survival of the cemiplimab group was significantly longer than the chemotherapy group The median overall survival of the cemiplimab group was significantly longer than the chemotherapy group The progression-free survival of the cemiplimab group was also significantly longer than the chemotherapy group The progression-free survival of the cemiplimab group was also significantly longer than the chemotherapy group

Overall survival of patients in two treatment groups divided into subgroups according to PD-L1 expression level

Overall survival of patients in two treatment groups divided into subgroups according to PD-L1 expression level

The objective response rate was 16.
4% in the cemiplimab group and 6.
3% in the chemotherapy group
.

The objective response rate was 18% for patients with PD-L1 expression ≥1% in the cemiplimab arm and 11% for patients with PD-L1 expression <1%

The objective response rate was 16.

adverse event

adverse event

Overall, the incidence of grade 3 or higher adverse events was 45.
0% in the cemiplimab group and 53.
4% ​​in the chemotherapy group
.

In conclusion, patients with cervical cancer who had relapsed after first-line platinum-based chemotherapy had significantly longer survival with cemiplimab than with continuation of single-agent chemotherapy
.

Survival was significantly longer with cemiplimab in patients with relapsed cervical cancer after first-line platinum-based chemotherapy than with continuation of single-agent chemotherapy
.

Survival was significantly longer with cemiplimab in patients with relapsed cervical cancer after first-line platinum-based chemotherapy than with continuation of single-agent chemotherapy

Original source:

Krishnansu S.

Survival with Cemiplimab in Recurrent Cervical CancerLeave a Comment here